Medical Treatment of Parkinson’s Disease

  • D. L. Xu
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 363)


Parkinson’s disease (PD) is a progressive neurodegenerative disease. It’s main feature is the nigrostriatal neuronal cell loss resulting in striatal dopamine (DA) deficiency. L-dopa + peripheral amino acid decarboxylase inhibitor (DDI: Sinemet or Madopar) is still the most effective agent for the symptomatic treatment of PD, but the dopa therapy is far from perfect. For advanced cases especially for patients with wearing off of the drug effect, fluctuation of response and “on-off, ” the conventional preparation such as Sinemet or Madopar due to their short T1/2 is no longer suitable for clinical use. Thus controlled release preparation e.g. Sinemet CR or Madopar HBS is preferable.


Striatal Dopamine Advanced Case COMT Inhibitor Progressive Neurodegenerative Disease Psychiatric Complication 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • D. L. Xu
    • 1
  1. 1.Department of Neurology Rui Jin HospitalShanghai Second Medical UniversityShanghaiChina

Personalised recommendations